Abstract: The invention relates to the use of a polypeptide derived from the adenylate cyclase of a Bordetella sp. (CyaA-derived polypeptide) by deletion of a segment of at least 93 amino acid residues, in particular a polypeptide derived from CyaA of Bordetella pertussis, as an immunomodifying antigen of the TH1/TH17-oriented immune response in an immunogenic composition. The invention relates to a vaccine candidate comprising such CyaA-derived polypeptide, either in an acellular immunogenic composition for active immunization against a condition causally related to the infection of a host by Bordetella sp. or in a combination composition encompassing said acellular immunogenic composition.

Abstract: The invention relates to the use of a polypeptide derived from the adenylate cyclase of a Bordetella sp. (CyaA-derived polypeptide) by deletion of a segment of at least 93 amino acid residues, in particular a polypeptide derived from CyaA of Bordetella pertussis, as an immunomodifying antigen of the TH1/TH17-oriented immune response in an immunogenic composition. The invention relates to a vaccine candidate comprising such CyaA-derived polypeptide, either in an acellular immunogenic composition for active immunization against a condition causally related to the infection of a host by Bordetella sp. or in a combination composition encompassing said acellular immunogenic composition.

Abstract: The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and for methods of utilizing the same.

Abstract: The invention provides a TLR agonist and an antibody which binds to an antigen such as a ?-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before the antibody or after the antibody. The compositions and methods provided are useful for prevention or treatment of Alzheimer's disease.

Abstract: The present invention relates to methods and compositions for preventing and reducing amyloid deposition in a subject by administering to the subject a composition containing aTLR4 agonist free of endotoxin, where the composition does not contain beta amyloid.

Abstract: The invention provides a TLR agonist and an antibody which binds to an antigen such as a ?-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before the antibody or after the antibody. The compositions and methods provided are useful for prevention or treatment of Alzheimer's disease.

Abstract: Compositions and methods comprising or using a combination of an adjuvant such as AS01B and an antigen such as a ?-amyloid antigen are provided. The compositions and methods provided are particularly useful for prevention or treatment of Alzheimer's disease. Suitable ?-amyloid antigens are A?1-5, A?1-6, A?1-7, A?1-10, A?1-14, A?1-15, A?2-7, A?2-8, A?3-7, A?3-8, A?11-16, A?11-17, A?p(E)3-7, A?p(E)3-8, A?p(E)3-40, A?p(E)3-42, A?p(E)11-16, A?p(E)11-17, A?p(E)11-40 or A?p(E)11-42, optionally with a protein carrier. Suitable adjuvants comprise QS21, 3D-MPL or an AGP, optionally in combination with a liposome.

Abstract: Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.

Abstract: Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.

Abstract: The present invention provides novel vaccine formulations for the treatment of cancer antigens. The vaccine comprises a modified MAGE-3 antigen, a NY-ESO-1 antigen, and an adjuvant comprising a saponin and a immunostimulatory oligonucleotide.

Abstract: The present invention relates fusion partners which act as immunological fusion partners, as expression enhancers, and preferably to fusion partners having both functions. In particular the fusion partners contain a so-called choline binding domain, for example fusions comprising LytA from Streptococcus pneumoniae, or the pneumococcal phage CP1 lysozyme (CPL1) wherein the choline binding domain is modified to include a heterologous T-helper epitope, and are fused to antigens, particularly poorly immunogenic antigens such as self-antigens, eg tumour specific or tissue specific antigens. The invention also relates to fusion proteins containing them, to their manufacture, to their use in immunogenic compositions and vaccines and to their use in medicines.

Abstract: The present invention relates to pharmaceutical/immunogenic compositions and methods for inducing an immune response against tumour-related antigens. More specifically, the invention relates to non-human prostate-specific antigens, more precisely to the non-human prostate-specific P501S, which can be used as xenogeneic antigen in prostate cancer vaccine therapy and as diagnostic agents for prostate tumours in humans, to immunogenic compositions containing them, to methods of manufacture of such compositions and to their use in medicine. Methods for formulating vaccines for immunotherapeutically treating P501S-expressing prostate tumors, prostatic hyperplasia, and prostate intraepithelilial neoplasia (PIN) are also provided.

Abstract: The present invention relates to novel vaccine therapies, and prophylactic treatments of atherosclerotic diseases. Accordingly there is provided, immunogens comprising apolipoproteins, or fragments or derivatives thereof, which in their native form the whole apolipoprotein has at least one of the following activities: (a) the inhibition of the binding of Apolipoprotein B to its receptor, and, or, (b) the inhibition of lipoprotein lipase. A preferred example of one such apolipoprotein is Apolipoprotein C-III (ApoCIII). The vaccines of the present invention, comprising said immunogens, are potent in the prevention, or reduction, of atherosclerotic plaque formation over prolonged periods of time, thereby reducing the potential of atheroslerosis leading to coronary or cerebrovascular disease.